8/10
08:00 am
jazz
Mount Sinai Awarded Three-Year Grant to Explore Therapeutic Approaches to KRAS Mutant Lung Tumors
Low
Report
Mount Sinai Awarded Three-Year Grant to Explore Therapeutic Approaches to KRAS Mutant Lung Tumors
8/10
02:03 am
jazz
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) was upgraded by analysts at StockNews.com from a "hold" rating to a "strong-buy" rating.
Low
Report
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) was upgraded by analysts at StockNews.com from a "hold" rating to a "strong-buy" rating.
8/5
08:04 am
jazz
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its price target lowered by analysts at HC Wainwright from $210.00 to $204.00.
Low
Report
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its price target lowered by analysts at HC Wainwright from $210.00 to $204.00.
8/4
02:03 pm
jazz
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its price target raised by analysts at BMO Capital Markets from $185.00 to $188.00. They now have an "outperform" rating on the stock.
Low
Report
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its price target raised by analysts at BMO Capital Markets from $185.00 to $188.00. They now have an "outperform" rating on the stock.
8/4
12:08 pm
jazz
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its price target raised by analysts at SVB Leerink LLC from $200.00 to $210.00. They now have an "outperform" rating on the stock.
Low
Report
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its price target raised by analysts at SVB Leerink LLC from $200.00 to $210.00. They now have an "outperform" rating on the stock.
8/4
12:07 pm
jazz
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its price target lowered by analysts at UBS Group AG from $194.00 to $191.00. They now have a "buy" rating on the stock.
Low
Report
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its price target lowered by analysts at UBS Group AG from $194.00 to $191.00. They now have a "buy" rating on the stock.
8/4
10:59 am
jazz
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "maintains" rating re-affirmed by analysts at Morgan Stanley.
Low
Report
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "maintains" rating re-affirmed by analysts at Morgan Stanley.
8/4
09:30 am
jazz
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "maintains" rating re-affirmed by analysts at UBS Group AG.
Low
Report
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "maintains" rating re-affirmed by analysts at UBS Group AG.
8/4
09:06 am
jazz
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "maintains" rating re-affirmed by analysts at SVB Leerink LLC.
Low
Report
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "maintains" rating re-affirmed by analysts at SVB Leerink LLC.
8/3
08:01 pm
jazz
Jazz Pharmaceuticals plc (JAZZ) CEO Bruce Cozadd on Q2 2022 Results - Earnings Call Transcript [Seeking Alpha]
Low
Report
Jazz Pharmaceuticals plc (JAZZ) CEO Bruce Cozadd on Q2 2022 Results - Earnings Call Transcript [Seeking Alpha]
8/3
04:05 pm
jazz
Jazz Pharmaceuticals Announces Second Quarter 2022 Financial Results and Affirms 2022 Financial Guidance
Low
Report
Jazz Pharmaceuticals Announces Second Quarter 2022 Financial Results and Affirms 2022 Financial Guidance
8/3
04:05 pm
jazz
Jazz Pharmaceuticals Announces Second Quarter 2022 Financial Results and Affirms 2022 Financial Guidance
Low
Report
Jazz Pharmaceuticals Announces Second Quarter 2022 Financial Results and Affirms 2022 Financial Guidance
8/2
11:02 pm
jazz
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
Low
Report
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
7/20
04:15 pm
jazz
Jazz Pharmaceuticals to Report 2022 Second Quarter Financial Results on August 3, 2022
Low
Report
Jazz Pharmaceuticals to Report 2022 Second Quarter Financial Results on August 3, 2022
7/20
04:15 pm
jazz
Jazz Pharmaceuticals to Report 2022 Second Quarter Financial Results on August 3, 2022
Low
Report
Jazz Pharmaceuticals to Report 2022 Second Quarter Financial Results on August 3, 2022
7/19
10:01 am
jazz
Avadel stock rises 8% as FDA grants tentative approval to its Jazz's sleep disorder drug rival [Seeking Alpha]
Low
Report
Avadel stock rises 8% as FDA grants tentative approval to its Jazz's sleep disorder drug rival [Seeking Alpha]
7/18
01:59 pm
jazz
Jazz Pharmaceuticals Is Trading on an Up Note [TheStreet.com]
Low
Report
Jazz Pharmaceuticals Is Trading on an Up Note [TheStreet.com]
7/1
06:01 pm
jazz
Axsome: One Step At A Time [Seeking Alpha]
Low
Report
Axsome: One Step At A Time [Seeking Alpha]
6/30
10:03 pm
jazz
Jazz Pharmaceuticals plc (
NASDAQ: JAZZ) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Low
Report
Jazz Pharmaceuticals plc (
NASDAQ: JAZZ) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
6/28
07:30 am
jazz
Jazz Pharmaceuticals Announces Top-line Results from Phase 3 Trial Evaluating Nabiximols Oromucosal Spray in Adult Participants with Multiple Sclerosis Spasticity
Low
Report
Jazz Pharmaceuticals Announces Top-line Results from Phase 3 Trial Evaluating Nabiximols Oromucosal Spray in Adult Participants with Multiple Sclerosis Spasticity
6/28
07:30 am
jazz
Jazz Pharmaceuticals Announces Top-line Results from Phase 3 Trial Evaluating Nabiximols Oromucosal Spray in Adult Participants with Multiple Sclerosis Spasticity
Low
Report
Jazz Pharmaceuticals Announces Top-line Results from Phase 3 Trial Evaluating Nabiximols Oromucosal Spray in Adult Participants with Multiple Sclerosis Spasticity
6/15
04:27 am
jazz
Redx to Get $5 Mln on Tumor Drug Milestone With US Regulator [MarketWatch]
Low
Report
Redx to Get $5 Mln on Tumor Drug Milestone With US Regulator [MarketWatch]
6/13
07:14 pm
jazz
Jazz Pharmaceuticals plc (
NASDAQ: JAZZ) is now covered by analysts at UBS Group AG. They set a "buy" rating on the stock.
Low
Report
Jazz Pharmaceuticals plc (
NASDAQ: JAZZ) is now covered by analysts at UBS Group AG. They set a "buy" rating on the stock.
6/10
01:05 am
jazz
Jazz Pharmaceuticals plc (
NASDAQ: JAZZ) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
Low
Report
Jazz Pharmaceuticals plc (
NASDAQ: JAZZ) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
6/7
07:30 am
jazz
Jazz Pharmaceuticals Presents Positive Data from Phase 2/3 Trial of Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn) in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma at the ASCO 2022 Annual Meeting
Medium
Report
Jazz Pharmaceuticals Presents Positive Data from Phase 2/3 Trial of Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn) in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma at the ASCO 2022 Annual Meeting